Abstract
September 5, 2020
The SARS-CoV-2 coronavirus has proven difficult to control not only because of its high transmissibility, but because those who are infected readily spread the virus before symptoms appear, and because some infected individuals, though contagious, never exhibit symptoms. Proactive testing of asymptomatic individuals is therefore a powerful, and probably necessary, tool for preventing widespread infection in many settings. This paper explores the effectiveness of alternative testing regimes, in which the frequency, the accuracy, and the delay between testing and results determine the time path of infection. For a simple model of disease transmission, we present analytic formulas that determine the effect of testing on the expected number of days of during which an infectious individual is exposed to the population at large. This allows us to estimate the frequency of testing that would be required to prevent uncontrolled outbreaks, and to explore the trade-offs between frequency, accuracy, and delay in achieving this objective. We conclude by discussing applications to outbreak control on college and university campuses.
Competing Interest Statement Ted Bergstrom and Haoran Li have no competing interests. Carl Bergstrom consults for Color Genomics on COVID testing schedules.
Competing Interest Statement
CTB consults for Color Genomics on COVID testing.
Funding Statement
No external funding supported this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a mathematical model with no human subjects involvement.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This is an analytic mathematical model. We have implemented a calculator for the formulas developed in the paper.
https://steveli.shinyapps.io/FrequencyAndAccuracyCalculator/
